Persistent telomere cohesion protects aged cells from premature senescence

Kameron Azarm¹, Amit Bhardwaj¹, Eugenie Kim¹ & Susan Smith¹

Human telomeres are bound by the telomere repeat binding proteins TRF1 and TRF2. Telomere shortening in human cells leads to a DNA damage response that signals replicative senescence. While insufficient loading of TRF2 at shortened telomeres contributes to the DNA damage response in senescence, the contribution of TRF1 to senescence induction has not been determined. Here we show that counter to TRF2 deficiency-mediated induction of DNA damage, TRF1 deficiency serves a protective role to limit induction of DNA damage induced by subtelomere recombination. Shortened telomeres recruit insufficient TRF1 and as a consequence inadequate tankyrase 1 to resolve sister telomere cohesion. Our findings suggest that the persistent cohesion protects short telomeres from inappropriate recombination. Ultimately, in the final division, telomeres are no longer able to maintain cohesion and subtelomere copying ensues. Thus, the gradual loss of TRF1 and concomitant persistent cohesion that occurs with telomere shortening ensures a measured approach to replicative senescence.

¹Kimmel Center for Biology and Medicine at the Skirball Institute, Department of Pathology, New York University School of Medicine, New York, NY 10016, USA. Email: susan.smith@med.nyu.edu
Human telomeres contain long double-stranded arrays of TTAGGG repeats that end in a 3’ single-stranded overhang and are bound by the six-subunit shelterin complex. Due to the inability of DNA polymerases to replicate the ends of linear molecules and to nucleolytic processing that generates the 3’ overhang, telomeres shorten following each round of replication. This shortening can be counteracted by telomerase, a reverse transcriptase that uses an RNA to add telomere repeats to the 3’ ends of chromosomes. During human development telomerase is down regulated. As a result, human somatic cells undergo telomere shortening, which acts as a molecular clock inducing cells to cease division and senescence. The loss of telomeric DNA leads to insufficient chromosome-end protection and to activation of a DNA damage response (DDR) at telomeres that signals p53-dependent irreversible cell cycle arrest. The demonstration that introduction of telomerase can rescue the senescence phenotype indicates that it is due to telomere shortening.

Telomere function is regulated by the TTAGGG double-stranded repeat binding shelterin subunits TRF1 and TRF2. TRF1 plays a role in telomere replication by facilitating replication through the telomere repeats and by regulating telomere length maintenance by telomerase. TRF1 function is aided by accessory binding proteins such as the poly (ADP-ribose) polymerase tankyrase. In addition to a role in telomere length regulation, is required for resolution of sister telomere cohesion. Cohesion between sister chromatids provides a template for recombination and repair during and after DNA replication. Maintenance of telomere cohesion in S phase relies on a third shelterin subunit TIN2 that binds to both TRF1 and TRF2. Resolution of telomere cohesion relies on TRF1-mediated recruitment of tankyrase 1 to telomeres in G2 phase.

TRF1 plays a distinct role at telomeres in chromosome end protection by facilitating formation of protective structures termed t-loops. Inactivation of TRF2 leads to a DDR at telomeres similar to that which occurs upon replicative senescence. The observation that overexpression of TRF2 can delay senescence onset suggests that the DDR in senescence is due to insufficient loading of shelterin at critically short telomeres. Loss of telomere function due to telomere shortening at a few chromosome ends is sufficient to induce arrest. Quantitative analysis indicates that an aggregate of at least five DDR-positive telomeres is necessary to induce senescence. It has been suggested that telomeres fluctuate through different protective states depending on the level of TRF2; an intermediate state, which activates the DDR, but does not promote telomere fusion, would permit cells to cycle until they reach a threshold that activates a p53-dependent senescence arrest.

Another feature of presenescent telomeres is that their resolution following DNA replication is delayed beyond S and G2 phase, into mitosis. Using fluorescent in situ hybridization (FISH) it was found that human telomeres remained unresolved (appeared as singlets) in metaphase in presenescent cells aged in culture and from early passage cells from aged individuals, whereas other chromosomal regions were resolved (appeared as doublets). The demonstration that introduction of telomerase into presenescent cells can rescue the metaphase telomere singlets suggests that they are due to telomere shortening. Depletion or knockout of tankyrase 1 leads to persistent telomere cohesion (FISH singlets in mitosis), reminiscent of the metaphase singlets in presenescence fibroblasts. However, the role of TRF1 and tankyrase 1 and the function of persistent cohesion in aged cells has not been determined.

Persistent telomere cohesion in mitosis has also been observed in ALT cells, telomerase negative cancer cells that maintain their telomeres through recombination-based mechanisms. In ALT cells persistent telomere cohesion was found to promote recombination between sister telomeres, while it suppressed inappropriate recombination between nonsisters. Although ALT cells have high levels of tankyrase 1 and TRF1, due to loss of ATRX (a common feature of ALT cells), tankyrase 1 is sequestered away from telomeres. Overexpression of tankyrase 1 in ALT cells forces resolution of sister telomere cohesion and induces excessive subtelomere recombination between nonhomologs, indicating a protective function for persistent telomere cohesion in ALT cancer cells. Whether persistent telomere cohesion plays a similar, protective role in senescing cells has not been determined.

Here, we show that insufficient loading of TRF1 at shorted telomeres protects aged cells from an abrupt recombination-induced DDR. We demonstrate that it is the shortened telomeres per se in any cellular context (aged normal cells, ALT cancer cells, or telomerase-inhibited telomerase positive cancer cells) that induce persistent telomere cohesion, providing an inherent protective mechanism that accompanies telomere shortening. Specifically, in aged cells, the gradual loss of telomere repeats concomitant with TRF1 deficiency-induced persistent cohesion, contributes to attenuated onset of senescence.

**Results**

TRF1 regulates telomere cohesion in aged fibroblasts. Tankyrase 1 binds to TRF1 through a consensus tankyrase binding site RGCADG in the amino terminal acidic domain of TRF1 (Supplementary Fig. 1a). To determine if resolution of telomere cohesion depends specifically on the tankyrase binding site in TRF1, we used CRISPR/Cas9 to mutate the essential terminal G of the RGCADG site in the endogenous TRF1 gene to P (TRF1.G18P) in HEK293T cells (Supplementary Fig. 1a). Multiple independent clones were isolated and sequenced (Supplementary Fig. 1b) and telomere cohesion analyzed by isolating mitotic cells using mechanical shake-off and probing with a chromosome specific subtelomere probe 16p (triploid in HEK293T cells). As shown in Fig. 1a, b, a WT clone displayed normal resolution of telomere cohesion (doublets), whereas the three TRF1.G18P mutant clones showed persistent telomere cohesion (singlets), confirming that resolution of telomere cohesion depends on the tankyrase binding site in TRF1.

As cells approach replicative senescence they exhibit persistent telomere cohesion, shown in Fig. 1c, d for aged WI38 cells and previously. During physiological telomere shortening shelterin components become limiting. Immunofluorescence analysis shows a decrease in TRF1 at aged cell telomeres (Supplementary Fig. 1c). We thus asked if there was insufficient TRF1 on aged cell telomeres to recruit tankyrase 1 for resolution of telomere cohesion. Overexpression of wild-type TRF1 (TRF1.WT) by transient transfection (20 h) in aged WI38 cells (Fig. 1e) led to its accumulation on telomeres, but not to recruitment of endogenous tankyrase 1 into telomeres (Fig. 1f and Supplementary Fig. 1d).Tankyrase 1 was sequestered away from telomeres in ALT cells with high levels of tankyrase 1 and TRF1, due to loss of ATRX (a common feature of ALT cells). Overexpression of tankyrase 1 in ALT cells forced resolution of sister telomere cohesion and induced excessive subtelomere recombination between nonhomologs, indicating a protective role for persistent telomere cohesion in ALT cancer cells. Whether persistent telomere cohesion plays a similar, protective role in senescing cells has not been determined.
Resolution of cohesion triggers subtelomere recombination. Previous studies showed that forcing resolution of cohesion in ALT cancer cells led to RAD51-dependent subtelomere recombination between nonhomologous sisters evidenced by an increase in the number of 16p subtelomere loci\(^31\). FISH analysis indicated an increase in the frequency of mitotic cells with greater than two 16p loci in aged WI38 cells transfected with TRF1.WT, but not Vector or TRF1.AA (Fig.1I, J), indicating that forced resolution of cohesion leads to subtelomere recombination in aged cells. Similar results were obtained in aged IMR90 cells (Supplementary Fig. 1j, k) and FISH analysis with the dual 13q subtelomere/arm probe showed that recombination was specific to the subtelomere (Supplementary Fig. 1l). To determine if the observed subtelomere recombination was dependent on RAD51, TRF1.WT transfected cells were treated with a RAD51 small molecule inhibitor (RAD51i). Resolution of telomere cohesion was unaffected by inhibition of RAD51 (Fig.1h), however subtelomere recombination was abrogated (Fig.1j), indicating that forced resolution of cohesion by overexpression of TRF1 leads to RAD51-dependent subtelomere recombination in aged cells.
To ascertain additional requirements for subtelomere recombination, we forced resolution of cohesion with TRF1.WT and interrogated cells with multiple small molecule inhibitors and siRNAs (Fig. 2a–c). Resolution of cohesion occurred under all conditions (Fig. 2a) demonstrating that the treatments did not inhibit resolution. However, subtelomere copying was inhibited in cells treated with ATR or CHK1 inhibitors (Fig. 2b). The requirement for CHK1 and ATR, along with RAD51 (shown in Fig. 1) suggests a homologous recombination mechanism for subtelomere copying. Recent studies in ALT cancer cells found that telomere recombination can proceed through multiple mechanisms, including POL3-dependent break-induced telomere synthesis36–38 and RAD52-dependent mitotic telomeric DNA synthesis39. However, the observation that subtelomere copying does not depend on RAD52, CHK2, or POL3 (Fig. 2b) indicates that it is distinct from these ALT telomere recombination pathways.

Finally, we asked if other subtelomeres (in addition to 16p) underwent copying by performing dual FISH analysis with subtelomere probes 13q and 16p (Fig. 2d–f) or 13q and 4p (Fig. 2g–i). Regardless of the probe used, aged WI38 cells transfected with TRF1.WT (but not TRF1.AA) showed a similar reduction in telomere cohesion (Fig. 2d, g) and a similar increase in subtelomere copying (Fig. 2e, h). To determine if multiple telomeres were undergoing recombination in the same cell, we asked what percentage of cells undergoing 13q copying also showed 16p or 4p copying. We found that 61% of TRF1.WT transfected cells that showed 13q copying also exhibited 16p copying (see Fig. 2f for example). Similarly, 72% of TRF1.WT transfected cells that showed 13q copying also showed 4p copying (see Fig. 2i for example). These data indicate that multiple subtelomeres undergo recombination in the same cell and (since the analysis is done within 20 h of transfection) in the same cell cycle.

Subtelomere recombination leads to premature senescence. As the RAD51-dependent subtelomere recombination appeared to occur at high frequency and at multiple subtelomeres, we asked if we could detect an increase in RAD51 foci upon forced resolution of cohesion. Overexpression of TRF1.WT, but not Vector or TRF1.AA, following lentiviral infection in aged WI38 cells (Supplementary Fig. 2a) led to a greater than three-fold increase in RAD51 foci overall (Fig. 3a, b), and a greater than four-fold increase in RAD51 foci associated with telomeres (Fig. 3c, d). To determine if the observed high level of subtelomere recombination coincided with a DDR, we used immunofluorescence analysis to measure the levels of γH2AX and 53BP1. Overexpression of TRF1.WT, but not Vector or TRF1.AA led to a two-fold increase in DNA damage foci (Fig. 3e, f), and a threefold increase in γH2AX foci associated with telomeres (Fig. 3g, h). The treatment of TRF1.WT overexpressing cells with the RAD51 inhibitor abrogated the increase in DNA damage (Fig. 3f). As we showed above that RAD51 is required for subtelomere recombination, but not for resolution of cohesion, these results indicate that subtelomere recombination drives the DNA damage.

To determine the impact of forced resolution of telomere cohesion on cell growth, we performed growth curve analysis following lentiviral infection of aged WI38 cells with TRF1 alleles. As shown in Fig. 3i, we observed a dramatic growth arrest specifically in TRF1.WT, but not Vector or TRF1.AA expressing cells. Introduction of the same TRF1 alleles into young WI38 cells had no effect on cell growth (Supplementary Fig. 2b, c), as expected and consistent with previous studies33. Inhibition of cell growth was due to premature activation of senescence as evidenced by an increase in the senescence associated marker β-galactosidase SA–β-gal40 (Fig. j, k) and in senescence associated heterochromatin foci (SAHF)41 (Fig. 3l, m) specifically in TRF1.WT cells. The premature senescence was abrogated by treatment of TRF1.WT cells with the RAD51 inhibitor (Fig. 3m), consistent with a role for subtelomere recombination-induced DNA damage in induction of premature senescence.

Checkpoint loss rescues TRF1-induced premature senescence. Next, to determine if induction of premature senescence was checkpoint dependent, we used SV40 Large T (LT) antigen to extend the proliferative life span of aged fibroblasts. We introduced a Vector or SV40-LT into WI38 cells at PD42 by retroviral infection. Once established, we allowed the cell lines to continue to grow until we observed slowing (pre senescence) of the Vector control cells, while SV40-LT cells continued to proliferate (PD6) (Fig. 4a). Telomere cohesion was measured at PD6 to determine if life-span extension interfered with persistent cohesion. As shown in Fig. 4b, c, both Vector and SV40-LT cells exhibited similar levels of persistent cohesion. However, SV40-LT cells showed an increase in subtelomere recombination compared with Vector (Fig. 4d), suggesting that the loss of the checkpoint permits a low level of subtelomere copying even with persistent cohesion.

We next introduced the Vector, TRF1.WT, and TRF1.AA alleles by lentiviral infection into WI38 SV40-LT PD6 cells (Fig. 4e). FISH analysis showed that TRF1.WT, but not Vector or TRF1.AA, forced resolution of telomere cohesion (Fig. 4f, g), as it had in aged WI38 cells. However, in contrast to aged WI38 cells, TRF1.WT-infected WI38 SV40-LT cells did not undergo growth arrest; they proliferated at the same rate as Vector or TRF1.AA cells (Fig. 4h), indicating that loss of the checkpoint abrogated the growth arrest. Since these cells continued to grow, we were able to analyze subtelomere copying at the standard early time point after infection (day 1) as well as later at day 4. TRF1.WT cells showed subtelomere copying on day 1 that increased dramatically (in frequency and number of subtelomeres copied) on day 4,
indicating runaway telomere copying in the absence of checkpoint-mediated growth arrest (Fig. 4i, j). FACS analysis showed that the increase in copying was not due to an increase in ploidy (Supplementary Fig. 3a). We also observed a slight increase in subtelomere copying in Vector and TRF1.AA cells from day 1 to day 4 (Fig. 4j), again indicating that loss of the checkpoint reveals a low level of subtelomere copying even with persistent cohesion.

**Fig. 2** The mechanism of Rad51-dependent subtelomere recombination. Quantification of the frequency of TRF1.AA or TRF1.WT transfected late (PDS0-53) WI38 mitotic cells (a) with cohered telomeres or (b) exhibiting subtelomere copying measured by FISH analysis with a 16p telo probe following treatment with the indicated inhibitors or siRNA. Average of two independent experiments (n ≥ 25 cells each). c Immunoblot analysis of TRF1.WT-transfected, POLD3 siRNA-treated late (PDS2) WI38 cell extracts. d, e Quantification of the frequency of WI38 TRF1.AA or TRF1.WT transfected late (PDS2-55) mitotic cells (d) with cohered telomeres or (e) exhibiting subtelomere copying measured by dual FISH analysis with 13q and 16p telo probes. Average of two independent experiments (n ≥ 46 cells each). f FISH analysis of a WI38 TRF1.WT transfected late (PDS5) mitotic cell exhibiting subtelomere copying using 13q (red) and 16p (green) telo probes. g, h Quantification of the frequency of TRF1.AA or TRF1.WT transfected late (PDS2) WI38 mitotic cells (g) with cohered telomeres or (h) exhibiting subtelomere copying measured by dual FISH analysis with 13q and 4p telo probes. Average of two independent experiments (n = 50 cells each). i FISH analysis of a TRF1.WT transfected late (PDS2) WI38 mitotic cell exhibiting subtelomere copying using 13q (red) and 4p (green) telo probes. DNA was stained with DAPI (blue). Scale bars represent 2 μm. Experiments were repeated independently twice (for c, f, i) with similar results. Source data are provided as a Source Data file.
TRF1 induces subtelomere recombination in ALT cells. Our studies thus far in normal primary cells suggest that telomere shortening that occurs in the absence of telomerase induces persistent telomere cohesion (resulting from the inability of limiting TRF1 to recruit tankyrase 1), which serves as a protective mechanism against subtelomere recombination, DNA damage, and premature activation of senescence. We sought to determine if a similar mechanism was at work in ALT cancer cells, which (like aged fibroblasts) exhibit persistent telomere cohesion. We previously identified an ATRX–macroH2A1.1–tankyrase axis, where the absence of ATRX freed the soluble macroH2A1.1 pool to sequester tankyrase 1 away from telomeres; we showed that overexpression of ATRX or tankyrase 1 in ALT cells forced resolution of telomere cohesion and led to Rad51-dependent subtelomere recombination.

**Figure Legends:**

(a) Example images showing the distribution of RAD51, TRF2, Merge/DAPI, TRF1:AA, TRF1:WT, and TRF1:Vec in WI38 PDS1 cells.

(b) Graph showing the percentage of cells with >5 RAD51 foci.

(c) Example images showing the distribution of RAD51, TRF2, Merge/DAPI, TRF1:AA, TRF1:WT, and TRF1:Vec in WI38 PDS1 cells.

(d) Graph showing the percentage of cells with >2 RAD51/53BP1 colocalizing foci.

(e) Example images showing the distribution of γH2AX, 53BP1, Merge/DAPI, Vector, TRF1:WT, and TRF1:AA in WI38 PDS1 cells.

(f) Graph showing the percentage of cells with >5 γH2AX/53BP1 colocalizing foci.

(g) Example images showing the distribution of γH2AX, TIN2, Merge/DAPI, Vector, TRF1:WT, and TRF1:AA in WI38 PDS1 cells.

(h) Graph showing the percentage of cells with >5 γH2AX/TIN2 colocalizing foci.

(i) Graph showing cell number over time for WI38 PDS2 cells transduced with Vector, TRF1:WT, and TRF1:AA.

(j) Example images showing the distribution of γH2AX, TIN2, Merge/DAPI, Vector, TRF1:WT, and TRF1:AA in WI38 PDS1 cells.

(k) Graph showing the percentage of cells showing SAHF.

(l) Example images showing the distribution of DAPI, Vector, TRF1:WT, and TRF1:AA in WI38 PDS1 cells.

(m) Graph showing the percentage of cells showing SAHF.
recombination. Although ALT cells have exceptionally long telomeres, they also harbor critically short ones due to the absence of telomerase. We thus asked if TRF1 was limiting for resolution of telomere cohesion in ALT cells. We introduced Vector, TRF1.WT, or TRF1.AA into GM847 ALT cells by transient transfection and performed immunofluorescence (Fig. 5a) and immunofluorescence (Fig. 5b) analysis. Both TRF1 alleles accumulated on ALT telomeres, but only TRF1.WT (not TRF1.AA) recruited endogenous tankyrase 1 (Fig. 5b and Supplementary Fig. 4a). FISH analysis with the 16p subtelomere probe (triploid in GM847 cells) showed that overexpression of TRF1.WT, but not Vector or TRF1.AA, led to resolution of persistent cohesion (Fig. 5c, d) and subtelomere recombination (Fig. 5e, f). Analysis of metaphase spreads showed that upon forced resolution of cohesion subtelomere sequences can be detected on additional chromosomes, consistent with subtelomere copying (Supplementary Fig. 4b-e). Subtelomere recombination was independent of POLD3 (Fig. 5g-i), indicating that subtelomere copying in ALT cells (as in aged cells) is distinct from POLD3-dependent break-induced telomere synthesis.

We next asked if forced resolution of cohesion and subtelomere recombination would have the same consequences in ALT cells as in normal aged cells, where we showed above that subtelomere recombination led to DNA damage and checkpoint-dependent premature senescence. We used lentiviral infection to introduce the vector, TRF1.WT, and TRF1.AA alleles into U2OS, a checkpoint proficient ALT cell line with wild-type p53 (Fig. 5j). Immunofluorescence analysis showed that TRF1.WT (but not Vector or TRF1.AA) led to induction of DNA damage (Fig. 5k, l) and to a growth arrest (Fig. 5m) due to activation of senescence, indicated by an increase in SAβ-gal positive cells (Fig. 5n, o), similar to the effect of TRF1.WT in aged cells and consistent with a checkpoint-mediated growth arrest. Unlike the aged fibroblasts, the nonnecessing U2OS cancer cells eventually continue growing. The growth arrest was unlikely due to a misregulation of ALT activity, as there was no change in the frequency of ALT-associated PML-bodies (a hallmark of the ALT pathway). Introduction of the same alleles into GM847, an ALT cell line lacking p53 checkpoint function, did not lead to a growth arrest (Supplementary Fig. 4f, g).

Telomerase resolves cohesion but suppresses recombination. Our data indicate that TRF1 is limiting for telomere resolution in two cell types that lack telomerase (ALT cancer cells and normal primary cells) suggesting that short telomeres drive the persistent cohesion. Previous studies showed that introduction of telomerase into normal aged cells rescued persistent telomere cohesion. We thus asked if telomerase could rescue persistent telomere cohesion in ALT cells. We introduced TERT/TR, a vector expressing the WT telomerase catalytic subunit and RNA into GM847 ALT cells by transient transfection and subjected the cells to immunoblot (Fig. 6a) and FISH (Fig. 6b) analysis. Introduction of telomerase rescued persistent telomere cohesion in ALT cells (Fig. 6b, c). Rescue depended on the catalytic activity of telomerase; a catalytically dead (CD) TERT/TR did not rescue persistent telomere cohesion (Fig. 6b, c). Interestingly, while telomerase expression (like TRF1 overexpression) forced resolution of cohesion in ALT cells, (unlike TRF1 overexpression), it did not lead to subtelomere recombination (Fig. 6d). Similar results were obtained upon introduction of telomerase into ALT U2OS cells (Supplementary Fig. 5a-d). The observation that telomerase can rescue persistent cohesion suggests that it is the critically short telomeres in ALT cells that give rise to persistent cohesion. The absence of subtelomere recombination upon forced resolution by telomerase further suggests that it is the critically short telomeres that are responsible for the subtelomere recombination.

The observation that persistent telomere cohesion can be rescued by introduction of telomerase suggests that persistent cohesion results directly from telomere shortening. To address this question we inhibited telomerase in a telomerase positive HTC75 cancer cell line (which like most other telomerase positive cells does not exhibit persistent telomere cohesion) with a small molecule inhibitor BIBR (1532). Cells were passaged long term (255 PDs) in the presence or absence of BIBR and telomere cohesion analyzed by 16p FISH (triploid in HTC75 cells) at early and late PDs (Fig. 6e). At the starting point (PD0) telomeres were resolved (Fig. 6f, g), as expected. Untreated BIBR cells showed resolved telomeres throughout the treatment period from PD0 to PD195 (Fig. 6f, g). By contrast, cells passaged in BIBR exhibited a gradual increase in persistent telomere cohesion (Fig. 6f, g) that accompanied telomere shortening, measured by telomere restriction fragment length analysis (Fig. 6h). These data indicate that persistent cohesion is induced by telomere shortening. We next determined the consequences of forcing resolution in these BIBR-treated HTC75 cells at late PD (245). We took two approaches to force resolution of cohesion: reactivation of telomerase or overexpression of TRF1 (Fig. 6i). For reactivation of telomerase, cells were split and grown in the presence or absence of BIBR for an additional 72 h. This treatment is sufficient to restore telomere length (Fig. 6i). FISH analysis shows that reactivation of telomerase leads to resolution of telomere cohesion (Fig. 6k), but not subtelomere recombination (Fig. 6l). Thus, similar to the results described above for ALT cells, telomerase forced resolution of cohesion, but at the
same time suppressed subtelomere recombination between the resolved and extended telomeres. For the second approach, we introduced Vector, TRF1.WT, or TRF1.AA into BIBR-treated HTC75 cells at PD245 by transient transfection (Supplementary Fig. 5e). TRF1.WT, but not Vector or TRF1.AA, forced resolution of telomere cohesion (Fig. 6m, n), similar to removal of BIBR. However, unlike removal of BIBR, TRF1.WT overexpression induced subtelomere recombination (Fig. 6o, p). Introduction of the same alleles into BIBR-treated HTC75 cells at PD245 by lentiviral infection (Supplementary Fig. 5f) showed that overexpression of TRF1.WT, but not Vector or TRF1.AA, led to an increase in RAD51 foci (Supplementary Fig. 5g, h) and DNA damage foci (Supplementary Fig. 5i, j), similar to results described above for normal aged cells and ALT cancer cells. We did not observe a growth arrest (Supplementary Fig. 5k), perhaps due in part to residual telomerase in the BIBR-treated cells.

Subtelomere recombination accompanies senescence onset. Our data suggest that as telomeres shorten, persistent telomere cohesion driven by insufficient TRF1 (and lack of tankyrase 1 recruitment), protects cells from subtelomere recombination and premature activation of senescence. The question remains, what ultimately triggers the senescence program. As described above,
when senescence was bypassed by introduction of SV40-LT, we observed a slight increase in subtelomere recombination, even without forcing resolution of telomere cohesion. We thus wondered if aged cells might ultimately succumb to subtelomere recombination, which would induce senescence. To address this question we passaged IMR90 cells until they senesced and then isolated mitotic cells by mechanical shake-off from the final passage (here defined by cessation of growth as PD51) and from two previous passages, and performed FISH with a 13q dual subtelomere/arm probe. As shown in Fig. 7a, b, at PD48 cells exhibited persistent telomere (but not arm) cohesion, as expected. However, at PD50 and 51 we observed a reduction in persistent telomere cohesion, as indicated by the decrease in persistent telomere cohesion. This is consistent with the idea that subtelomere recombination, which is induced by the loss of telomere cohesion, leads to senescence. To further support this hypothesis, we tested whether the introduction of siPOLD3, which decreases telomere cohesion, would lead to an increase in subtelomere recombination. As shown in Fig. 7c, d, the introduction of siPOLD3 led to a significant increase in subtelomere recombination, as indicated by the increase in percent mitotic cells with single telomere loci. We also observed an increase in the percent mitotic cells with >3 16p loci, which is consistent with the idea that subtelomere recombination leads to the loss of telomere cohesion and the induction of senescence. To further support this hypothesis, we tested whether the introduction of siPOLD3 would lead to an increase in the percent cells with >5 γH2AX/53BP1 colocalizing foci, which is a marker of DNA damage. As shown in Fig. 7e, f, the introduction of siPOLD3 led to a significant increase in the percent cells with >5 γH2AX/53BP1 colocalizing foci, as indicated by the increase in percent cells with >5 γH2AX/53BP1 colocalizing foci. Finally, we tested whether the introduction of siPOLD3 would lead to an increase in the percent SA-Bgal-positive cells, which is a marker of senescence. As shown in Fig. 7g, h, the introduction of siPOLD3 led to a significant increase in the percent SA-Bgal-positive cells, as indicated by the increase in percent SA-Bgal-positive cells.
Telomere cohesion (Fig. 7a, b). We next asked if this natural loss of cohesion was accompanied by subtelomere copying. We performed FISH analysis and scored four categories of 13q FISH signals: 2arm/2tel0 (normal ploidy); >2arm/>2tel0 (aneuploidy); >2arm/2tel0 (arm copying); and 2arm/>2tel0 (telomere copying) (Fig. 7c). We observed an increase in ploidy as has been described previously. In addition, we observed an increase in subtelomere (but not arm) copying at PD50 and 51 that was abrogated by RAD51 inhibition (Fig. 7d, e). Similar results were obtained with W138 cells at their final passage (defined by cessation of growth as PD54) (Fig. 7f–j). Together these data suggest that as telomeres shorten and cells approach senescence, transient persistent telomere cohesion protects cells from subtelomere recombination and premature senescence, but ultimately telomere erosion results in loss of telomere cohesion, RAD51-dependent subtelomere recombination, and senescence activation.

Discussion

Telomere shortening serves as a molecular clock to count the cell divisions leading to replicative senescence. Concomitant with loss of TTAGGG repeats is loss of the shelterin TTAGGG-repeat binding proteins TRF1 and TRF2. Previous studies show how loss of TRF2 could signal senescence onset. Here, we show the impact of TRF1 loss. As telomeres shorten, the inability to recruit sufficient TRF1 and as a result tankyrase 1 leads to persistent telomere cohesion in mitosis, which we suggest, protects shortened telomeres from inappropriate recombination and DNA damage-induced senescence. This persistent cohesion however only affords transient protection; ultimately telomeres are unable to maintain cohesion and cells succumb to subtelomere recombination and growth arrest.

Persistent cohesion appears to be an ineluctable consequence of telomere shortening. It occurs in normal human cells as they approach senescence and their telomeres become critically short and in ALT cells, which lack telomerase and exhibit critically short telomeres at high frequency. In both cases, the observation that it can be rescued by telomerase expression indicates telomere shortening as the basis. Conversely, our demonstration that persistent cohesion can be induced in telomerase positive cancer cells through telomerase inhibition supports the notion that persistent cohesion is inherent to short telomeres.

Our data suggest that persistent cohesion protects cells from illegitimate subtelomere recombination. Upon forced resolution of cohesion, subtelomere recombination occurs rapidly, at high frequency, and across multiple cell types. Recombination can be induced at similar frequency in aged cells, ALT cancer cells, and telomerase-inhibited telomerase positive cancer cells. A common feature of these cells is that their telomeres have gone through many rounds of division in the absence of telomerase. Such telomeres are likely to have a subpopulation that are critically short.

In the absence of telomerase, telomeres may accumulate single stranded DNA and may be eroded into the subtelomeres and thereby likely to be engaged in strand invasion and copying. Persistent cohesion, which has been shown to promote recombination between sisters in normal human cells and in ALT cells, may benefit critically short telomeres by permitting repair, while at the same time preventing release and engagement of recombination with nonsisters. The observation that telomerase expression (when coupled to forced resolution of cohesion) abrogates subtelomere recombination, indicates short telomeres as the basis.

Although subtelomere copying in human cells was first detected in ALT, we now demonstrate that the phenomenon is not unique to ALT cells; it can occur in any cell type that lacks telomerase and has shortened telomeres. The dependence on ATR, CHK1, and RAD51 indicate that it may rely on mechanisms that facilitate long range telomere movement. The lack of dependence on RAD52 and POLD3 indicate that it is distinct from DNA damage-induced mechanisms of telomere synthesis in ALT 36-39. In fact, in contrast to mechanisms of telomere recombination in ALT cells, which take advantage of elevated levels of DNA damage at telomeres to promote telomere recombination for telomere extension and cell growth, subtelomere copying actually induces DNA damage and halts cell growth. Thus, persistent cohesion (in any cell type) may serve a protective role by providing shortened (perhaps endogenously damaged) telomeres with a sister for DNA repair and by preventing damage-inducing subtelomere recombination with nonsisters.

We show that persistent cohesion protects aged cells from premature senescence, but ultimately at the final division cohesion is lost, subtelomere copying ensues, and cells senesce. Maintenance of telomere cohesion requires the shelterin subunit TIN2. Thus, it is likely that critically short telomeres lacking both TRF1 and TRF2 can no longer recruit sufficient TIN2 to maintain cohesion, thereby unleashing subtelomere recombination and DNA damage. Indeed, we showed that senescence bypass by inactivation of the DNA damage checkpoint leads to a rapid and dramatic increase in subtelomere copying. Thus, when telomere shortening is unchecked, subtelomere recombination ensues. Ultimately, cells will go through crisis and only those that develop telomere maintenance mechanisms will survive. In the case of ALT cancer cells, persistent cohesion may promote survival by providing a safe harbor for critically short telomeres.
**Methods**

**Cell lines.** WI38 and IMR90 fibroblast cell lines (ATCC) were supplemented with 20% FBS and grown in standard conditions. For aged WI38, cells were analyzed at PD 50–55. For aged IMR90, cells were analyzed at PD 48-52. ALT cancer cell lines GM847 and U2OS (ATCC), and the telomerase-positive cancer cell lines HEK293T (ATCC) and HTC7511 (obtained from Dr. Titia de Lange) were supplemented with 10% FBS and grown in standard conditions. Where indicated, the following inhibitors were dissolved in DMSO and added to the culture media 16 h prior to harvest: Rad51 inhibitor RI-1 (Selleckchem, 20 µM), Rad52 inhibitor AICAR (Selleckchem, 20 µM), ATR inhibitor VE-821 (Selleckchem, 10 µM), CHK1 inhibitor SB 218078 (Tocris, 250 nM), and CHK2 inhibitor (Sigma, 10 µM).
**Fig. 6 Telomerase suppresses subtelomere recombination.**

a Immunoblot analysis of transfected GM847 cell extracts. b FISH analysis of transfected GM847 mitotic cells using a 16p (triploid in GM847 cells) telo probe (green). Quantification of the frequency of mitotic cells (c) with cohered telomers or (d) exhibiting subtelomere copying. Average of two independent experiments (n ≥ 40 cells each). e Experimental setup for monitoring telomere cohesion in BIBR-treated HTCC57 cells. f FISH analysis of HTCC57 mitotic cells at P0 and upon long-term treatment without (PD195) or with (PD209) BIBR using a 16p (triploid in HTCC57 cells) telo probe (green). g Quantification of the frequency of mitotic cells with cohered telomers. Average of two independent experiments (n ≥ 40 cells each). h Analysis of telomere restriction fragments isolated from BIBR-treated HTCC57 cells, fractionated on agarose gel, denatured, and probed with a 32P-labeled CCCTAA probe. White bars indicate mean telomere length. i Experimental setup for resolving telomere cohesion in BIBR-treated HTCC57 cells at PD245. j FISH analysis of BIBR-treated HTCC75 (PD245) mitotic cells that were split and grown with (+) or without (−) BIBR for 72 h using a 16p telo probe (green). k Quantification of the frequency of mitotic BIBR-treated HTCC75 (PD245) cells (k) with cohered telomers or (l) exhibiting subtelomere copying upon continued treatment with (+) or without (−) BIBR for 72 h. Average of two independent experiments (n ≥ 28 cells each). m FISH analysis of Vector, TRFI.WT, or TRFI.AA transfected BIBR-treated HTCC75 (PD245) mitotic cells using a 16p telo probe (green). n Quantification of the frequency of mitotic cells with cohered telomers. Average of two independent experiments (n ≥ 32 cells each). o FISH analysis of a TRFI.WT transfected BIBR-treated (PD245) HTCC75 mitotic cell exhibiting subtelomere copying (arrowhead) using a 16ptelo probe (green). p Quantification of the frequency of mitotic cells exhibiting subtelomere copying. Average of two independent experiments (n ≥ 32 cells each). b, f, j, m, o DNA was stained with DAPI (blue). Scale bars represent 2 µm. Experiments were repeated independently twice (for a, b, f, h, j, m, o) with similar results. Source data are provided as a Source Data file.

**Generation of TRFI mutant cell lines using CRISPR/Cas9.** The tankyrase binding site (13RGCADG18) in the acidic domain of TRFI was mutated using RNA-guided CRISPR associated nuclease Cas9. A 20 bp target sequence directed against the first exon of the human TRFI gene (TERFI) (TRFI guide DNA 5′-CCGGGCTGCTGCGCATGTT-3′) was inserted into the guide sequence insertion site using BsaI site of the CRISPR plasmid pX330 comprised of Cas9 and a chimeric guide RNA. A single stranded DNA homology template was designed to change Gly18 to Pro (TRFI.G18P) and also to introduce a BamHI restriction site. Lentiviral infection

**Plasmids.** MycTRFI.WT50 contains an N-terminal myc epitope tag followed by amino acids 2–439 in the pLPC retroviral vector. MycTRFI.AA183 was generated using site-directed mutagenesis (Agilent) of the MycTRFI.WT plasmid using the sense oligonucleotide 5′-CCGGGCTGCTGCGCATGTT-3′ and the reverse primer 5′-GACGGGCGCGTACGACAC-3′. Three isolated independent homologous TRFI.G18P clones (#1, #3, and #5) based on BamHI restriction digestion pattern of TRFI.WT and AA were cloned into the NheI and SalI sites of the pLPC retroviral vector. For growth curve analyses, target cells were infected for 48 h. Following 24 h of selection, cells were seeded into either 24-well plates (for WI38 and WI38 SV40 LT cells) or 6-well plates (for U2OS and HTCC75 BIBR (+) PD245) at 10,000 cells/well in media containing 2 µg/ml puromycin. The next day (Day 0), cells were harvested and counted using a hemocytometer and used to normalize the number of cells plated. Cells were then harvested and counted every 24 h over the next 5 days. Cell numbers were calculated as a ratio of the “Day 0” counts. Three technical replicates were done for each data point.

**SV40 LT immortalization of WI38 cells.** For SV40 Large T antigen infection, amphotrophic retroviruses were generated by transfecting 20 µg of pBabe-neoLargeTcDNA56 into Phoenix Amphotropic cells (ATCC) using calcium phosphate precipitation. Five h following transfection, fresh media was added. 24 h following transfection, retroviral supernatants were collected every 6 or 12 for 48 h. Collected virus was filtered through 0.45 µm filter and suspended through 10% FBS and 4 µg/ml polybrene. Target WI38 cells were infected with retrovirus for 24 h, followed by a 24-h recovery in standard media. Cells were then selected in 600 µg/ml geneticin (Gibco) for long-term culturing.

**Long-term telomerase inhibition with BIBR 1532.** Telomerase-positive HTCC57 cells were treated with the TERT inhibitor BIBR 1532 (Selleckchem) at a final concentration of 20 µM for ~250 population doublings. Cells were passaged approximately every 4 days (replated at a 1:8 dilution), and inhibitor was freshly added at each passage.

**Preparation of cell extracts.** Cells were resuspended in four volumes of TNE buffer [10 mmol/L Tris (pH 7.8), 1% Nonidet P-40, 0.15 M NaCl, 1 mmol/L EDTA, and 2.5% protease inhibitor cocktail (Sigma)] and incubated for 1 h on ice. Suspensions were pelleted at 8000 x g for 10 min. Equal amounts of supernatant proteins (determined by Bio-Rad protein assay) were fractionated by SDS-PAGE and analyzed by immunoblotting.

**Immunoblot analysis.** Immunoblots were incubated separately with the following primary antibodies: rabbit anti-Myc (0.1 µg/ml; Santa Cruz #sc-7989), mouse anti-Flag (3.8 µg/ml; Sigma #F3165), rabbit anti-TERT 375 (1:500 dilution of crude serum), raised against Escherichia coli-derived fusion protein containing hTERT amino acids 702-841, mouse anti-BIP/90 (1:300 dilution; Abnova #H0007T-M01), or mouse anti-α-tubulin antibody (1:10000–1:20000; Sigma #T5158), followed by horseradish peroxidase-conjugated donkey anti-rabbit or sheep antilguine IgG (1:3000, Amersham #NA934 or #NA931). Bound antibody was detected with Super Signal West Pico (Thermo Scientific).

**Telomere restriction fragment analysis.** Genomic DNA was isolated from DMSO- or BIBR 1532-treated HTCC57 cell lines and digested with HinfI, AaI, and Rat. Approximately 3 µg of the digested DNA was fractionated on a 1% agarose gel. Telomeres were detected by hybridization to a 32P end-labeled (CCCTAA), oligonucleotide probe as previously described15. Fluorescence-activated cell sorting (FACS): Following trypsinization at ~70% confluence, cells were resuspended in PBS containing 2 mM EDTA, fixed with cold 70% (vol/vol) ethanol, treated with RNase A (ThermoFisher, 200 µg/ml), stained with propidium iodide (50 µg/ml), and analyzed with a Becton, Dickinson FACS Calibur and CellQuest Pro software. The data were modeled using Flowjo.
v9 software after eliminating doublets by gating to determine relative DNA content and polyploidy. Approximately 20,000 events were analyzed for each condition.

**Chromosome-specific FISH.** Cells were isolated mechanically by mitotic shake-off and fixed twice in 1 mL methanol:acetic acid (3:1) for 15 min. The 250 uL of cell suspension were cytospun (Shandon Cytospin) at 452 × g for 2 min onto slides, rehydrated in 2X SSC at 37 °C for 2 min, and dehydrated in an ethanol series of 70, 80, and 95% for 2 min each. Cells were denatured at 75 °C for 2 min and hybridized overnight at 37 °C with FITC-conjugated (16ptelo or 4ptelo) or TRITC-conjugated (13qtelo) subtelomere probes, or FITC-conjugated subtelomere and TRITC-conjugated arm 13q14.3 deletion probe (13qtelo/13qarm) from Cytocell. Cells were washed in 0.4X SSC at 72 °C for 2 min, and in 2X SSC with 0.05% Tween 20 at RT for 30 s. DNA was stained with 0.2 µg/ml DAPI. For FISH analysis of transfected WI38 and IMR90 fibroblasts, cells were treated with 50 ng/ml nocodazole (Sigma) for 16 h prior to shake-off. Mitotic cells were scored as having telomeres cohered (singlets) if 50% or more of their loci appeared as singlets, i.e., one out of two or two out of three.

**Chromosome-specific FISH on metaphase spreads.** For metaphase spreads, cells were treated with 0.5 µg/ml colcemide for 8 h, harvested by trypsinization,
hypotonically swollen in 10 mM Tris pH 7.4, 10 mM NaCl, and 5 mM MgCl2, for 10 min at 37 °C, and fixed twice for 15 min in methanol/acetic acid (3:1). Metaphase spreads were prepared by dropping fixed cells on coverslips followed by centrifugation at 180 × g for 10 s in an Eppendorf 5810 R centrifuge. Coverslips were air-dried overnight and processed for chromosome-specific FISH as described above.

**Indirect immunofluorescence.** Cells were fixed in 2% paraformaldehyde in PBS for 10 min at RT, permeabilized in 0.5% NP-40/PBS for 10 min at RT, blocked in 1% BSA/PBS, and incubated with mouse anti-Häs 4A6 (1.0 µg/ml; Milipore #05-724) and rabbit anti-tankyrase 1 762 (1.4 µg/ml)57, mouse anti-yHAX2 clone BW301 (1 µg/ml; Milipore #05-636) and rabbit anti-S3BP1 (4 µl/g/ml; Novus Biologicals #NB100-304) or rabbit anti-TIN2 701 (0.36 µg/ml)58, or rabbit anti-TRF1 415 (0.2 µg/ml)59 and human anti-centromere (ACA) (1:4000) antibodies. For Rad51 and TRF2 coimmuno- localization, cells were permeabilized in Triton X-100 buffer for 10 min at RT, blocked in 1% BSA/PBS, and incubated with rabbit anti-RAD51 (4 µg/ml; Santa Cruz #sc-8349) and mouse anti-TRF2 (2.5 µg/ml; Image 11MG-124A). Primary antibodies were incubated at RT for 2 h, followed by detection with FITC- conjugated or TRITC-conjugated donkey anti-rabbit or antimouse antibodies (1:100; Jackson Laboratories #711-025-152 or #711-095-152). DNA was stained with 0.2 µg/ml DAPI.

**Detection of senescence-associated heterochromatin foci (SAHF).** SAHF was analyzed on coverslips processed for yHAX2 and S3BP1 immunofluorescence described above. A cell was scored as SAHF-positive if its DAPI counterstain had a characteristic punctate pattern40. SAHF was quantified as described above. A cell was scored as SAHF-positive if its DAPI counterstain had a characteristic punctate pattern40.

Senescence-associated β-galactosidase assay: For the SA-β-galactosidase assay40, cells were fixed in 2% formaldehyde and 0.2% glutaraldehyde in PBS for 5 min, washed three times in PBS, and stained for either 4 hr (for WI38 cells) or 12 hr (for U2OS cells) at 37 °C in staining solution (1 mg/mL X-gal, 150 mM NaCl, 2 mmol/L MgCl2, 5 mmol/L K3Fe[CN]6, 5 mmol/L K4Fe[CN]6, and 40 mmol/L NaPi, pH 6.0).

**Image acquisition.** FISH and immunofluorescence images were acquired using a microscope (Axioplan 2; Carl Zeiss, Inc.) with a Plan Achromat 63X NA 1.4 oil immersion lens (Carl Zeiss, Inc.) and a digital camera (C4742-95; Hamamatsu Photonics). Images were acquired and processed using Openlab software (Perkin Elmer). For chromosome specific FISH, if foci fell in more than one optical plane of focus, multiple planes were merged using Openlab software. SA-β Gal staining images were imaged with brightfield at x20 magnification using a Zeiss AxiosObserver.Z1 microscope and a AxioCam 503 camera.

**Statistical analysis.** Statistical analysis was performed using Prism 8 software. Data points are shown as dot plots. Student unpaired two-sided t test was applied. P < 0.05 values were considered significant: *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001; ns, not significant.

**Reporting summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**Data availability**

The Source Data underlying the following Figures: 1b, d, e, h, j; 2a–e, g, h; 3b, d, f, h, i, k, m; 4a, c-e, g, h, j; 5a, d, f, i, m, o; 6a, c, d, g, h, k, l, n, p; and 7b, c, e, g, h, j, and Supplementary Figs.: 1d, f, h, i, k, l; 2a–c, 4a, c-e, f, g, and 5a, c-e, h, j, k are provided in the Source Data File. All data are available from the corresponding author upon reasonable request. Source data are provided with this paper.

**Edited by:** Mark T. Bayley

**Funding:** This research was conducted with the support of the Netherlands Cancer Institute, the Netherlands Organization for Health Research and Development, and the Dutch Kidney Foundation.

**Conflicts of interest:** All authors declare no competing interests.

**Acknowledgments:** Detailed analysis was performed by Daniëlle van der Meulen, Yvonne Stokman, and Teun Ruizenaar, and all authors read and approved the final version of the manuscript.

**Data availability**

The data used in this study are available from the corresponding author on reasonable request.

**References**

1. de Lange, T. Shelterin: the protein complex that shapes and safeguards human telomeres. *Genes Dev.* 19, 2100–2110 (2005).

2. Huffman, K. E., Levene, S. D., Tesmer, V. M., Shay, J. W. & Wright, W. E. Telomere shortening is proportional to the size of the G-rich telomeric 3′-overhang. *J. Biol. Chem.* 275, 19719–19722 (2000).

3. Verma, P., Takai, H. & de Lange, T. Telomeric 3′ overhangs derive from resection by Exo1 and Apollo and fill-in by POT1-associated CST. *Cell* 150, 39–52 (2012).

4. Greider, C. W. & Blackburn, E. H. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. *Cell* 43, 405–415 (1985).

5. Greider, C. W. & Blackburn, E. H. The telomere terminal transferase of *Tetrahymena* is a ribonucleoprotein enzyme with two kinds of primer specificity. *Cell* 51, 887–898 (1997).

6. Wright, W. E., Piatsyszek, M. A., Rainey, W. R., Byrd, W. & Shay, J. W. Telomerase activity in human germline and embryonic tissues and cells. *Dev. Genet.* 18, 173–178 (1996).

7. Harley, C. B., Futcher, A. B. & Greider, C. W. Telomeres shorten during aging of human fibroblasts. *Nature* 345, 458–460 (1990).

8. d’Adda di Fagagna, F. et al. A DNA damage checkpoint response in telomere-initiated senescence. *Nature* 426, 194–198 (2003).

9. Bodnar, A. G. et al. Extension of life-span by introduction of telomerase into human fibroblasts. *Nature* 345, 356–360 (1990).

10. Normal human cells [see comments].

11. van Steensel, B. & de Lange, T. Control of telomere centromeric cohesion by the Scc3 homologues SA1 and SA2, respectively, in human cells. *J. Cell Biol.* 148, 745–755 (2000).

12. Bhardwaj, A., Yang, Y., Ueberheide, B. & Smith, S. Whole proteome analysis. *Cell* 134, 1003–1013 (2008).

13. Smith, S., Giriat, I., Schmitt, A. & de Lange, T. Tankyrase, a poly(ADP-ribose) transferase that inhibits its poly(ADP-ribose) polymerase activity. *J. Biol. Chem.* 273, 7436–7442 (1998).

14. Smith, S., Giriat, I., Schmitt, A. & de Lange, T. Telomere overhangs derive from resection by Exo1 and Apollo and fill-in by POT1-associated CST. *Cell* 150, 39–52 (2012).

15. van Steensel, B., Smogorzewska, A. & de Lange, T. TRF2 protects human telomeres from end-to-end fusions. *Cell* 92, 401–413 (1998).
22. Takai, H., Smogorzewska, A. & de Lange, T. DNA damage foci at dysfunctional telomeres. Mol. Cell 12, 1489–1498 (2003).
23. Karlseder, J., Smogorzewska, A. & de Lange, T. Senescence induced by altered telomere state, not telomere loss. Science 295, 2446–2449 (2002).
24. Zou, Y., Sfeir, A., Gryaznov, S. M., Shay, J. W. & Wright, W. E. Does a sentinel or a subset of short telomeres determine replicative senescence? Mol. Biol. Cell 15, 3709–3718 (2004).
25. Karlseder, J., Cesare, A. J., Huschtscha, L. I., Neumann, A. A. & Reddel, R. R. Five dysfunctional telomeres predict onset of senescence in human cells. EMBO Rep. 13, 52–59 (2011).
26. Cesare, A. J., Hayashi, M. T., Crabbe, L. & Karlseder, J. The telomere deprotection response is functionally distinct from the genomic DNA damage response. Mol. Cell 51, 141–153 (2013).
27. Usami, S. et al. Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions. Nat. Struct. Mol. Biol. 16, 1244–1251 (2009).
28. Ofir, R. et al. Replication and/or separation of some human telomeres is delayed beyond S-phase in pre-senescent cells. Chromosoma 111, 147–155 (2002).
29. Yalon, M., Gal, S., Segev, Y., Selig, S. & Skorecki, K. L. Sister chromatid separation at human telomeric regions. J. Cell Sci. 117, 1961–1970 (2004).
30. Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A. & Reddel, R. R. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines [see comments]. Nat. Med. 3, 1271–1274 (1997).
31. Ramamoorthy, M. & Smith, S. Loss of ATRX Suppresses Resolution of Telomere Cohesion to Control Recombination in ALT Cancer Cells. Cancer Cell 28, 357–369 (2015).
32. Lovejoy, C. A. et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet. 8, e1002772 (2012).
33. Sbodio, J. I. & Chi, N. W. Identification of a tankyrase-binding motif shared by IRAP, TAB182, and human TRF1 but not mouse TRF1. NuMA contains this RXXPDG motif and is a novel tankyrase partner. J. Biol. Chem. 277, 31887–31892 (2002).
34. Kim, M. K. & Smith, S. Persistent telomere cohesion triggers a prolonged anaphase. Mol. Biol. Cell 25, 30–40 (2014).
35. Hsiao, S. J. & Smith, S. Tankyrase function at telomeres, spindle poles, and beyond. Biochemie 90, 83–92 (2008).
36. Dilley, R. L. et al. Break-induced telomere synthesis underlies alternative telomere maintenance. Nature 539, 54–58 (2016).
37. Roumelioti, F. M. et al. Alternative lengthening of human telomeres is a conservative DNA replication process with features of break-induced replication. EMBO Rep. 17, 1731–1737 (2016).
38. Sobinoff, A. P. et al. BLM and SLX4 play opposing roles in recombination-dependent replication at human telomeres. EMBO J. 36, 2907–2919 (2017).
39. Min, J., Wright, W. E. & Shay, J. W. Alternative lengthening of telomeres mediated by mitotic DNA synthesis engages break-induced replication processes. Mol. Cell Biol. 37, 1–16 (2017).
40. Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363–9367 (1995).
41. Narita, M. et al. RB-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113, 703–716 (2003).
42. Henson, J. D., Neumann, A. A., Yeager, T. R. & Reddel, R. R. Alternative lengthening of telomeres in mammalian cells. Oncogene 21, 598–610 (2002).
43. Damm, K. et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. Embo J. 20, 6958–6968 (2001).
44. Pascolo, E. et al. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleoside drug candidate. J. Biol. Chem. 277, 15566–15572 (2002).
45. Sherwood, S. W., Rush, D., Ellsworth, J. L. & Schinke, R. T. Defining cellular senescence in IMR-90 cells: a flow cytometric analysis. Proc. Natl Acad. Sci. USA 85, 9086–9090 (1988).
46. Danioloski, Z. & Smith, S. Loss of tumor suppressor STAG2 promotes telomere recombination and extends the replicative lifespan of normal human cells. Cancer Res 77, 5530–5542 (2017).
47. Cho, N. W., Dilley, R. L., Lampson, M. A. & Greenberg, R. A. Interchromosomal homology searches drive directional ALT telomere movement and synthesis. Cell 159, 108–121 (2014).
48. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84–87 (2014).
49. Ran, F. A. et al. Double nicking by RNA-guided CRISPR-Cas9 for enhanced genome editing specificity. Cell 154, 1380–1389 (2013).
50. Chang, W., Dynek, J. N. & Smith, S. TRF1 is degraded by ubiquitin-mediated proteolysis after release from telomerases. Genes Dev. 17, 1328–1333 (2003).
51. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997).
52. Wong, J. M. & Collins, K. Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita. Genes Dev. 20, 2848–2858 (2006).
53. Hahn, W. C. et al. Inhibition of telomerase limits the growth of human cancer cells [see comments]. Nat. Med. 5, 1164–1170 (1999).
54. Naldini, L. et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263–267 (1996).
55. Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L. & Trono, D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15, 871–875 (1997).
56. Hahn, W. C. et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol. Cell Biol. 22, 2111–2123 (2002).
57. Scherlian, H. et al. Mammalian meiotic telomeres: protein composition and redistribution in relation to nuclear pores. Mol. Biol. Cell 11, 4189–4203 (2000).
58. Houghtaling, B. R., Cuttonaro, L., Chang, W. & Smith, S. A dynamic molecular link between the telomere length regulator TRF1 and the chromosome end protector TRF2. Curr. Biol. 14, 1621–1631 (2004).
59. Cook, B. D., Dynek, J. N., Chang, W., Shostak, G. & Smith, S. Role of the PoxV poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres. Mol. Cell Biol. 22, 332–342 (2002).

Acknowledgements

We thank Smith lab members and Tom Meier for critical reading of the manuscript. Research reported in this publication was supported by the National Institutes of Health under award number R01CA200751 to S.S. and F31CA221162 to K.A.

Author contributions

K.A., A.B., and E.K. performed experiments. K.A., A.B., E.K., and S.S. designed experi-

Competing Interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at https://doi.org/10.1038/s41467-020-17133-4.

Correspondence and requests for materials should be addressed to S.S.

Peer review information Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2020